Latest Breaking News On - Foamix pharmaceuticals - Page 2 : comparemela.com
Regulation - US FDA, Dermatologicals, Denmark
thepharmaletter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepharmaletter.com Daily Mail and Mail on Sunday newspapers.
Could Saghmos Therapeutics join the ranks of Triad public companies? Biotech founders mull IPO, SPAC as options
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.Follow @coryrenauer
Shares of beaten-down biotech stock
Vyne Therapeutics (NASDAQ:VYNE) jumped more than 30% higher on Jan. 25, 2021, in response to a relatively minor development for its new acne treatments. In a nutshell, the company executed a contract that could boost sales of its recently launched products.
Millions of teenagers and adults eager to prevent spots from erupting on their faces could push sales of Vyne Therapeutics new treatments through the roof. That said, independent new drug launches rarely progress as quickly as investors expect.
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
HERZLIYA, Israel, Jan. 06, 2021 PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations.
Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing. Prior to joining PainReform, Mrs. Keynan served as Executive Director of Drug Development at VYNE Therapeutics Ltd., formerly Foamix Pharmaceutical
Acne Vulgaris Market Segmentation, Parameters and Prospects 2020 to 2026 Market Research Report
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.